GW&K Investment Management LLC Has $7.93 Million Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)

GW&K Investment Management LLC trimmed its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTXGet Rating) by 17.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 255,476 shares of the company’s stock after selling 55,042 shares during the quarter. GW&K Investment Management LLC’s holdings in Travere Therapeutics were worth $7,930,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Advisor Group Holdings Inc. raised its position in shares of Travere Therapeutics by 1,448.0% during the third quarter. Advisor Group Holdings Inc. now owns 1,161 shares of the company’s stock worth $28,000 after purchasing an additional 1,086 shares during the period. Royal Bank of Canada raised its position in shares of Travere Therapeutics by 132.7% during the second quarter. Royal Bank of Canada now owns 4,053 shares of the company’s stock worth $59,000 after purchasing an additional 2,311 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Travere Therapeutics by 50.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,860 shares of the company’s stock worth $134,000 after purchasing an additional 1,640 shares during the period. Teacher Retirement System of Texas bought a new stake in Travere Therapeutics during the third quarter worth $202,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Travere Therapeutics during the fourth quarter worth $227,000.

In other Travere Therapeutics news, Director Steve Aselage sold 2,575 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $21.92, for a total value of $56,444.00. Following the sale, the director now owns 146,919 shares of the company’s stock, valued at approximately $3,220,464.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP William E. Rote sold 1,563 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $21.71, for a total value of $33,932.73. Following the completion of the sale, the senior vice president now directly owns 43,672 shares in the company, valued at approximately $948,119.12. The disclosure for this sale can be found here. Insiders have sold a total of 5,399 shares of company stock worth $117,501 in the last three months. 4.71% of the stock is currently owned by insiders.

TVTX has been the subject of several recent research reports. Zacks Investment Research upgraded Travere Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 28th. HC Wainwright upped their price target on Travere Therapeutics from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, May 17th. Finally, Piper Sandler decreased their price target on Travere Therapeutics from $42.00 to $40.00 in a report on Friday, May 6th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $33.50.

NASDAQ:TVTX traded down $0.42 during trading on Friday, reaching $24.18. The company’s stock had a trading volume of 772,852 shares, compared to its average volume of 912,684. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -7.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.80, a quick ratio of 5.23 and a current ratio of 5.28. The firm has a 50 day moving average of $26.00 and a 200-day moving average of $27.35. Travere Therapeutics, Inc. has a 12 month low of $12.75 and a 12 month high of $31.65.

Travere Therapeutics (NASDAQ:TVTXGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.35). The firm had revenue of $48.49 million for the quarter, compared to the consensus estimate of $51.92 million. Travere Therapeutics had a negative return on equity of 70.33% and a negative net margin of 88.46%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.96) EPS. Equities research analysts forecast that Travere Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

About Travere Therapeutics (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

See Also

Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTXGet Rating).

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.